for the period ended 30 September 2007; currency in US Dollars
CALGARY, Nov. 30 /CNW/ - Epicore BioNetworks Inc. reports the results of its first quarter of fiscal year 2008 operations. Epicore's business got off to a good start in fiscal 2008 with sales increasing over a record prior year quarter one. Although Epicore's first fiscal quarter one historically has been its weakest, the last two years have bucked this trend because of strong southern hemisphere sales. Revenues increased 5% over prior year ($615,600 versus $587,000). Gross profit decreased slightly ($398,700 versus $422,700). Expenses at $346,100 were 5% above prior year quarter one as the Company increased marketing expenses. The Company recorded net income of $39,800 versus $93,600 in prior year quarter one. Net income per share for the current quarter was $0.002 versus $0.004 in prior year quarter one. Cash reserves increased $0.26 million over fiscal 2007 year-end as prior period sales were collected.
Epicore sales revenue increased $28,600 over prior year quarter one, which previously was the strongest quarter one in Company history. Quarterly sales reflected the Company's commitment to aquaculture and its strong position in the world shrimp aquaculture markets. Aquaculture represented over 97% of sales. Latin America was the largest sales region with the non-Ecuador hatchery sector substantially ahead of prior year. Ecuador remained our largest sales country despite lower sales in the farm sector due to intense competition. Our EPICIN-in-feed farm program continued to offer Ecuadorian farmers the best performance for the money but lower unit-priced probiotics took market share. Our Ecuadorian hatchery sales benefited from new products, such as our low cost EPILITE liquid feeds and new EPICIN-G2 probiotic. Sales grew in Central and the rest of South America as our EPIFEED-MBF maturation feed gained popularity and as Brazil began to cope with IMNV virus.
Sales increased in Asia as major hatcheries employed Epicore products in their switch from Penaeus monodon to Penaeus vannamei. Epicore's experience and contacts in Latin America opened doors with these Asian groups. The region represents 80% of world shrimp aquaculture potential and now contributes a significant percentage of Epicore sales. Recent Asian success shows that the Company's years of effort and investments were well worth it.
Non-aquaculture sales grew strongly because of the RootX municipal distribution deal signed last year.
Quarterly operating expenses were slightly higher than prior period ($0.35 versus $0.33 million) due to increased marketing efforts and higher corporate expenses.
Cash at the end of September was $0.50 million versus $0.16 million in prior year. Operating activities, including changes in non-cash working capital balances, produced $0.3 million of cash during quarter one versus prior year when these activities consumed $0.2 million of cash. While market conditions remain difficult in several regions, the Company has positioned itself well to succeed in the important markets. Long-term prospects for Epicore technology remain attractive.
The financial statements of the Company have been prepared in accordance with Canadian GAAP. Epicore BioNetworks Inc. is a public corporation with a registered office in Calgary, Alberta, Canada and with shares listed on the TSX Venture Exchange (symbol EBN). (The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.)
This press release contains forward-looking statements that involve significant risks and uncertainties. The actual results, performance or achievements of the Company might differ materially from the results, performance or achievements of the Company expressed or implied by such forward-looking statements. Such forward-looking statements include, without limitation, those regarding the development plans of the Company and the expected timing and results of such development. We can provide no assurance that such development will proceed as currently anticipated or that the expected timing or results of such development will be realized. We are subject to various risks, including the uncertainties of product development, markets for our products and regulatory review, our need for additional capital to fund our operations, our reliance on collaborative partners, our history of losses, and other risks inherent in the biotechnology industry.